-
Mashup Score: 3
The new radiotracer flurpiridaz is poised to make a major impact on nuclear cardiology. Timothy Bateman, MD, co-director of the cardiovascular radiologic imaging program at Saint Luke’s Mid America Heart Institute, shared details on the tracer in a new interview.
Source: cardiovascularbusiness.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Flurpiridaz data shows promise to expand and enhance cardiac PET - 2 year(s) ago
The biggest news from the American Society of Nuclear Cardiology (ASNC) 2022 meeting was positive late-breaking data on the phase 3 Aurora trial for the flurpiridaz (F-18) positron emission tomography (PET) radiotracer agent. Numerous nuclear cardiology experts have predicted the radiopharmaceutical might significantly accelerate PET adoption in nuclear cardiology with its 106 minute half life…
Source: Cardiovascular BusinessCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Flurpiridaz data shows promise to expand and enhance cardiac PET #cardiacPET #Nuclearcardiology #ASNC #ASNC22 #ASNC2022 #Flurpiridaz https://t.co/bW0Fbb8gFP
-
-
Mashup Score: 2Flurpiridaz Clinical Trial Results Will be Announced at ASNC2022 - 2 year(s) ago
August 12, 2022 — The results of “A Phase 3, Open-label, Multicenter Study of Flurpiridaz (F18) Injection for Positron Emission Tomography (PET) Imaging Assessment of Myocardial Perfusion in Patients Referred for Invasive Angiography Because of Suspected Coronary Artery Disease (CAD)” will be presented for the first time at ASNC’s 27th Annual Scientific Session and Exhibition, which will…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @MyASNC Results of “A Phase 3, Open-label, Multicenter Study of #Flurpiridaz Injection for #PET Imaging Assessment of #MyocardialPerfusion in Patients Referred for Invasive #Angiography Because of Suspected #CAD” will be presented at #ASNC22: https://t.co/pZKixcaMht
-
Video - Flurpiridaz is poised to make a major impact on nuclear cardiology. Tim Bateman, MD, explains details on the AURORA trial. #ASNC @MyASNC #PET #Flurpiridaz #Nuclearimaging https://t.co/9m59nmyrWU